Reston – November 30, 2016 – Cooley advised Aclaris Therapeutics on its $104.7 million follow-on offering, which includes the full exercise of the underwriters’ option to purchase additional shares.

Aclaris, which trades on the NASDAQ Global Select Market under the symbol “ACRS,” is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing novel drugs to address unmet needs in dermatology.

Cooley advised Aclaris on its $63.3 million IPO in October 2015 and a $20 million private placement in May 2016.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.